class action lawsuit

Portnoy Law Firm launches class action against Apollo Global Management alleging undisclosed Epstein communications. Stock declined 5-6% following February 2026 media revelations.

Boston Scientific faces class action lawsuit after 17% stock decline following $0.45 EPS miss versus $0.48-$0.52 guidance, amid alleged undisclosed Electrophysiology market share losses.

Nektar Therapeutics faces class action lawsuit over alleged failure to disclose enrollment protocol violations in failed Phase 2b REZOLVE-AA trial, triggering 8% stock decline.

Driven Brands faces securities lawsuit over material accounting errors spanning 2023-2025. Stock fell 40% after February disclosure; investors have until May 8, 2026 to claim lead plaintiff status.

Trip.com faces class action lawsuit alleging securities fraud over undisclosed antitrust risks. Stock fell 19% after China's January 2026 investigation.

$DRVN stock crashed 40% after material accounting restatements spanning 2023-2025. Class action deadline for investors with $100K+ losses set for May 8, 2026.

Soleno Therapeutics ($SLNO) faces class action lawsuit alleging executives failed to disclose material safety concerns with its lead drug DCCR, with lead plaintiff deadline set for May 5, 2026.

Navan faces securities lawsuit over allegedly undisclosed $95 million Q3 sales-marketing expense surge; investors with $100K+ losses have until April 2026 to file.

FDA rejects Corcept's lead drug candidate, triggering 50% stock plunge and securities class action lawsuit. Lead plaintiff deadline set for April 21, 2026.

Enphase Energy shareholders must file lead plaintiff applications by April 20, 2026 in a class action alleging disclosure failures regarding inventory management and tax credit impacts.

Driven Brands ($DRVN) restated financials after discovering material errors; stock fell 30.2%. Investors can seek lead plaintiff status until May 8, 2026.

Plug Power faces securities fraud lawsuit alleging DOE loan overstatements. Class period: January-November 2025. Investors can seek lead plaintiff status by April 3, 2026.

Snowflake faces class action lawsuit alleging false statements about product efficiency, with stock down 18% during June 2023-February 2024 period. Lead plaintiff applications due April 2026.

Driven Brands ($DRVN) stock plummeted 40% after disclosing accounting errors requiring financial restatement. Securities lawsuit filed for investors who bought between May 2023 and February 2026.

Soleno Therapeutics faces securities fraud lawsuit over alleged safety misstatements in DCCR clinical trial. Stock fell 26% following August short-seller report.

Kirby McInerney LLP filed class action lawsuit against $TCOM for allegedly understating regulatory risks before January 2026 stock plunge.

Securities class action filed against NuScale Power over misrepresented ENTRA1 partnership. $495M payment revealed, expenses surged 3,000%, stock down 70% from highs.

Soleno Therapeutics faces securities fraud lawsuit alleging failure to disclose safety concerns about DCCR drug candidate between March 2025 and November 2026.

Soleno Therapeutics faces class action lawsuit over DCCR safety concealment claims, with investors suffering significant losses following critical short-seller report and patient death disclosure.

Law firm launches class action against $CWH over alleged misstatements on inventory management and demand forecasts between April 2025 and February 2026.